Aim: To compare and analyze dose constraints and target coverage results and to reduce Bladder Wall (Bwall) V18.12 for prostate Stereotactic-Body Radiation Therapy (SBRT) when Seminal Vesicles (SSVV) are included or not. Several indicators based on intersection volumes are obtained to predict constraint fulfillment. Background: Due to prostate’s low alpha-beta ratio and the possibility of increasing the therapeutic ratio several moderate and extreme hypofractionation schemes have been proposed. The scheme selected was a fivefraction urethra-sparing prostate SBRT. Materials and Methods: 150 patients divided into two groups according to the inclusion of SSVV in PTV or not were analyzed. Histograms, average values, standard deviations and degrees of fulfillment were obtained for each constraint or goal and group. A possible reduction of the Bwall V18.12 was addressed by re-optimizing fifty randomly chosen patients. Predictors of constraint fulfilling were obtained by using the intersections of Bwall and Rectum Wall (Rwall) with the PTV. Results: Significant differences in Rwall V32.62 and V29 were obtained when evaluating the influence of SSVV inclusion. A reduction of 12% in the Bwall V18.12 constraint was achieved without compromising coverage and OARs doses. No dependence on the inclusion of SSVV was found. Conclusions: Statistically significant differences have been found in Rwall intermediate-dose constraint when SSVV was included. A reduction of 12% in the Bwall V18.12 constraint has been achieved without compromising the PTV coverage and the rest of OARs constraints. Constraint fulfillment predictors could be useful to evaluate the feasibility of prostate SBRT prior to the planning process for every single patient.
References
[1]
Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. https://doi.org/10.3322/caac.21590
[2]
National Cancer Institute (2021) Cancer Stat Facts: Cancer of Any Site: Number of New Cases and Deaths. https://seer.cancer.gov/statfacts/html/all.html
[3]
Schaeffer, E., et al. (2021) NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Official Journal of the National Comprehensive Cancer Network. 19, 134-143.
https://doi.org/10.6004/jnccn.2021.0008
[4]
Kishan, A.U., Karnes, R.J., Romero, T., Wong, J.K., Motterle, G., Tosoian, J.J., et al. (2021) Comparison of Multimodal Therapiues and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features. JAMA Neteork Open, 4, Article No. e2115312.
https://doi.org/10.1001/jamanetworkopen.2021.15312
[5]
Kupelian, P.A., Potters, L., Khuntia, D., Ciezki, J.P., Reddy, C.A., Reuther, A.M., Carlson, T.P. and Klein, E.A. (2004) Radical Prostatectomy, External Beam Radiotherapy<72Gy, External Beam Radiotherapy ≥72Gy, Permanent Seed Implantation, or Combined Seeds/External Beam Radiotherapy for Stage T1-T2 Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 58, 25-33.
https://doi.org/10.1016/S0360-3016(03)00784-3
[6]
Dandapani, S.V. and Sanda, M.G. (2008) Measuring Health-Related Quality of Life Consequences from Primary Treatment for Early-Stage Prostate Cancer. Seminars in Radiation Oncology, 18, 67-72. https://doi.org/10.1016/j.semradonc.2007.10.001
[7]
Kupelian, P.A., Willoughby, T.R., Reddy, C.A., Klein, E.A. and Mahadevan, A. (2007) Hypofractionated Intensity-Modulated Radio-Therapy (70 Gy at 2.5 Gy per Fraction) for Localized Prostate Cancer: Cleveland Clinic Experience. International Journal of Radiation Oncology, Biology, Physics, 68, 1424-1430.
https://doi.org/10.1016/j.ijrobp.2007.01.067
[8]
Yeoh, E.E., Holloway, R.H., Fraser, R.J., Botten, R.J., Matteo, A.C.D., Butters, J., Weerasinghe, S. and Abeysinghe, P. (2006) Hypofractionated versus Conventionally Fractionated Radiation Therapy for Prostate Carcinoma: Updated Results of a Phase III Randomized Trial. International Journal of Radiation Oncology, Biology, Physics, 66, 1072-1083. https://doi.org/10.1016/j.ijrobp.2006.06.005
[9]
Pollack, A., Walker, G., Horowitz, E.M., Price, R., Feigenberg, S., Konski, A.A., Movsas, B. (2013) Randomized Trial of Hypofractionated External Beam Radiotherapy for Prostate Cancer. Journal of Clinical Oncology, 31, 3860-3868.
https://doi.org/10.1200/JCO.2013.51.1972
[10]
Arcangeli, A., Saracino, B., Gomellini, S., Petrongari, M.G., Arcangeli, S., Sentinelli, S., Marzi, S., Landoni, V., Fowler, J. and Strigari, L. (2010) A Prospective Phase III Randomized Trial of Hypofractionation versus Conventional Fractionation in Patients with High Risk Prostate Cáncer. International Journal of Radiation Oncology, Biology, Physics, 78, 11-18. https://doi.org/10.1016/j.ijrobp.2009.07.1691
[11]
Fowler, J.F., Toma-Dasu, J. and Dasu, A. (2013) Is the Alpha-Beta Ratio for Prostate Tumors Really Low and Does it Vary with the Level of Risk at diagnosis? Anticancer Research, 33, 1009-1011.
[12]
Vogelius, I.R. and Bentzen, S.M. (2013) Meta-Analysis of the Alpha/Beta Ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News, or No News? International Journal of Radiation Oncology, Biology, Physics, 85, 89-94. https://doi.org/10.1016/j.ijrobp.2012.03.004
[13]
Vogelius, I.R. and Bentzen, S.M. (2018) Dose Response and Fractionation Sensitivity of Prostate Cancer after External Beam Radiation Therapy: A Meta-Analysis of Randomized Trials. International Journal of Radiation Oncology, Biology, Physics, 100, 858-865. https://doi.org/10.1016/j.ijrobp.2017.12.011
[14]
van Leeuwen, C.M., Oei, A.L., Crezee, J., Bel, A., Franken, N.A.P., Stalpers, L.J.A. and Kok, H.P. (2018) The Alfa and Beta of Tumours: A Review of Parameters of The Linear-Quadratic Model, Derived From Clinical Radiotherapy Studies. Radiation Oncology, 13, Article No. 96. https://doi.org/10.1186/s13014-018-1040-z
[15]
Avkshtol, V., Dong, Y., Hayes, S.B., Hallman, M., Price, R., Sobczak, M., Horwitz, E. and Zaorsky, N. (2016) A Comparison of Robotic Arm versus Gantry Linear Accelerator Stereotactic Body Radiation Therapy for Prostate Cancer. Research and Reports in Urology, 8, 145-148. https://doi.org/10.2147/RRU.S58262
[16]
Zaorsky, N.G., Harrison, A.S., Trabulsi, E.J., Gomella, L.G., Showalter, T.N., Hurwitz, M.D., Dicker, A.P. and Den, R.B. (2013) Evolution of Advanced Technologies in Prostate Cancer Radiotherapy. Nature Reviews Urology, 10, 565-579.
https://doi.org/10.1038/nrurol.2013.185
[17]
Kim, D.N., Straka, C., Cho, L.C., Lotan, Y., Yan, J., Kavanagh, B., Raben, D., Cooley, S., Brindle, J., Xie, X.J., Pistenmaa, D. and Timmerman, R. (2017) Early and Multiple PSA Bounces Can Occur Following High-Dose Prostate Stereotactic Body Radiation Therapy: Subset Analysis of a Phase 1/2 Trial. Practical Radiation Oncology, 7, e43-e49.
https://doi.org/10.1016/j.prro.2016.06.010
[18]
Jackson, W.C., Silva, J., Hartman, H.E., et al. (2019) Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated on Prospective Studies. International Journal of Radiation Oncology, Biology, Physics, 104, 778-789.
https://doi.org/10.1016/j.ijrobp.2019.03.051
[19]
Kim, D.W., Cho, L.C., Straka, C., Christie, A., Lotan, Y., Pistenmaa, D., Kavanagh, B.D., Nanda, A., Kueplian, P., Brindle, J., Cooley, S., Perkins, A., Raben, D., Xie, X.-J. and Timmerman, R.D. (2014) Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial Of Stereotactic Body Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 89, 509-517.
https://doi.org/10.1016/j.ijrobp.2014.03.012
[20]
Serra, M., Ametrano, G., Borzillo, V., Quarto, M., Muto, M., Franco, R.D., Savino, F., Filomena, L. and Muto, P. (2020) Dosimetric Comparison among Cyberknife, Helical Tomotherapy and VMAT for Hypofractionated Treatment in Localized Prostate Cancer. Medicine, 99, Article No. e23574.
https://doi.org/10.1097/MD.0000000000023574
[21]
Smeenk, R.J., The, B.S., Butler, E.B., van Lin, E.N. and Kaanders, J.H. (2010) Is There a Role for Endorectal Balloons in Prostate Radiotherapy? A Systematic Review. Radiotherapy and Oncology, 95, 277-282. https://doi.org/10.1016/j.radonc.2010.04.016
[22]
Chapet, O., Udrescu, C., Devonec, M., Tanguy, R., Sotton, M.-P., Enachescu, C., et al. (2013) Prostate Hypofractionated Radiation Therapy: Injection of Hyaluronic Acid to Better Preserve the Rectal Wall. International Journal of Radiation Oncology, Biology, Physics, 86, 72-76. https://doi.org/10.1016/j.ijrobp.2012.11.027
[23]
Weber, D.C., Zilli, T., Vallee, J.P., Rouzaud, M., Miralbell, R. and Cozzi, L. (2012) Intensity Modulated Proton and Photon Therapy for Early Prostate Cancer with or without Transperineal Injection of a Polyethylene Glycol Spacer: A Treatment Planning Comparison Study. International Journal of Radiation Oncology, Biology, Physics, 84, S357, 2370. https://doi.org/10.1016/j.ijrobp.2012.07.942
[24]
Isacsson, U., Nilsson, K., Asplund, S., Morhed, E., Montelius, A. and Turesson, I. (2010) A Method to Separate the Rectum from the Prostate during Proton Beam Radiotherapy of Prostate Cancer Patients. Acta Oncologica, 49, 500-505.
https://doi.org/10.3109/02841861003745535
[25]
Shimizu, S., Nishioka, K., Suzuki, R., Shinohara, N., Maruyama, S., Abe, T., et al. (2014) Early Results of Urethral Dose Reduction and Small Safety Margin in Intensity-Modulated Radiation Therapy (IMRT) for Localized Prostate Cancer Using a Real-Time Tumor-Tracking Radiotherapy (RTRT) System. Radiation Oncology, 9, Article No. 118. https://doi.org/10.1186/1748-717X-9-118
[26]
Chen, L.N., Suy, S., Uhm, S., Oermann, E.K., Ju, A.W., Chen, V., et al. (2013) Stereotactic Body Radiation Therapy (SBRT) for Clinically Localized Prostate Cancer: The Georgetown University Experience. Radiation Oncology, 8, Article No. 58.
https://doi.org/10.1186/1748-717X-8-58
[27]
Vainshtein, J., Abu-Isa, E., Olson, K.B., Ray, M.E., Sandler, H.M, Normolle, D., et al. (2012) Randomized Phase II Trial of Urethral Sparing Intensity Modulated Radiation Therapy in Low-Risk Prostate Cancer: Implications for Focal Therapy. Radiation Oncology, 7, Article No. 82. https://doi.org/10.1186/1748-717X-7-82
[28]
Harsolia, A., Vargas, C., Yan, D., Brabbins, D., Lockman, D., Liang, J., et al. (2007) Predictors for Chronic Urinary Toxicity after the Treatment of Prostate Cancer with Adaptive Three-Dimensional Conformal Radiotherapy: Dose-Volume Analysis of a Phase II Dose-Escalation Study. International Journal of Radiation Oncology, Biology, Physics, 69, 1100-1109. https://doi.org/10.1016/j.ijrobp.2007.04.076
[29]
Ghadjar, P., Zelefsky, M.J., Spratt, D.E., Munck af Rosenschöld, P., Oh, J.H., Hunt, Ma., et al. (2014) Impact of Dose to the Bladder Trigone on Long-Term Urinary Function after High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 88, 339-344.
https://doi.org/10.1016/j.ijrobp.2013.10.042
[30]
Kole, T.P., Tong, M., Wu, B., Lei, S., Obayomi, O., Chen, L.N., et al. (2016) Late Urinary Toxicity Modeling after Stereotactic Body Radiotherapy (SBRT) in the Definitive Treatment of Localized Prostate Cancer. Acta Oncologica, 55, 52-58.
https://doi.org/10.3109/0284186X.2015.1037011
[31]
King, C.R., Freeman, D., Kaplan, I., Fuller, D., Bolzicco, G., Collins, S., et al. (2013) Stereotactic Body Radiotherapy for Localized Prostate Cancer: Pooled Analysis from a Multi-Institutional Consortium of Prospective Phase II Trials. Radiotherapy and Oncology, 109, 217-221. https://doi.org/10.1016/j.radonc.2013.08.030
[32]
King, C.R., Collins, S., Fuller, D., Wang, P.C., Kupelian, P., Steinberg, M., et al. (2013) Health-Related Quality of Life after Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Results from a Multi-Institutional Consortium of Prospective Trials. International Journal of Radiation Oncology, Biology, Physics, 87, 939-945.
https://doi.org/10.1016/j.ijrobp.2013.08.019
[33]
Miralbell, R., et al. (2014) Stereotactic Body Radiotherapy for CT1c-CT3a Prostate Cancer with a Low Risk of Nodal Metastases (< 20%, Roach Index): A Novalis Circle Phase II Prospective Randomized Trial. ClinicalTrials.gov Identifier NCT01764646.
[34]
Katz, A.J. and Kang, J. (2014) Stereotactic Body Radiotherapy as Treatment for Organ Confined Low- and Intermediate Risk Prostate Carcinoma: A 7-Year Study. Frontiers in Oncology, 4, Article No. 240. https://doi.org/10.3389/fonc.2014.00240
[35]
Meier, R., Beckman, A., Henning, G., Mohideen, N., Woodhouse, S.A., Cotrutz, C. et al. (2016) Five-Year Outcomes from a Multicenter Trial of Stereotactic Body Radiation Therapy for Low-and-Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 96, S33-S34.
https://doi.org/10.1016/j.ijrobp.2016.06.094
[36]
Mantz, C. (2014) A Phase II Trial of Stereotactic Ablative Body Radiotherapy for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real Time Target Tracking: Report of Toxicity, Quality of Life and Disease Control Outcomes with 5-Year Minimum Follow-Up. Frontiers in Oncology, 4, Article No. 279.
https://doi.org/10.3389/fonc.2014.00279
[37]
Brand, D.H., Tree, A.C., Ostler, P., van der Voet, H., Loblaw, A., Chu, W., Raben, D., Nanda, A., Cooley, S., Kim, D.W.N., Pistenmaa, D., Lotan, Y. and Timmerman, R. (2019) Intensity-Modulated Fractionated Radiotherapy versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): Acute Toxicity Findings from an International, Randomized, Open-Label, Phase III, Non-Inferiority Trial. The Lancet Oncology, 20, 1531-1543. https://doi.org/10.1016/S1470-2045(19)30569-8
[38]
Hannan, R., Tumati, V., Xie, X.J., Cho, L.C., Kavanagh, B.D., Brindle, J., et al. (2016) Stereotactic Body Radiation Therapy for Low and Intermediate Risk Prostate Cancer: Results from a Multi-Institutional Clinical Trial. European Journal of Cancer, 59, 142-151. https://doi.org/10.1016/j.ejca.2016.02.014
[39]
Loblaw, A., Cheung, P., D’Alimonte, L., Deabreu, A., Mamedov, A., Zhang, L., et al. (2013) Prostate Stereotactic Ablative Body Radiotherapy Using a Standard Linear Accelerator: Toxicity, Biochemical and Pathological Outcomes. Radiotherapy and Oncology, 107, 153-158. https://doi.org/10.1016/j.radonc.2013.03.022
[40]
Roach III, M., Marquez, C., Yuo, H.S., Narayan, P., Coleman, L., Nseyo, U.O., et al. (1994) Predicting the Risk of Lymph Node Involvement Using the Pre-Treatment Prostate Specific Antigen and Gleason Score in Men with Clinically Localized Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 28, 33-37.
https://doi.org/10.1016/0360-3016(94)90138-4
[41]
Dubouloz, A., Rouzaud, M., Tsvang, L., Verbakel, W., Björkqvist, M., Linthout, N., Lencart, J., Pérez-Moreno, J.M., Ozen, Z., Escude, L., Zilli, T. and Miralbell, R. (2018) Urethra-Sparing Stereotactic Body Radiotherapy for Prostate Cancer: How Much Can the Rectal Wall Dose Be Reduced with or without an Endorectal Balloon? Radiation Oncology, 13, Article No. 114. https://doi.org/10.1186/s13014-018-1059-1
